Gene Therapy Researcher Faked Data

A former postdoc in a prominent gene therapy lab is branded a fraud by the US government more than three years after having a slew of papers retracted from various journals.

Written byBob Grant
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, LUPAA former postdoc who studied gene therapy at the Mount Sinai School of Medicine in New York is guilty of research misconduct, according to the US government’s Office of Research Integrity (ORI). Retraction Watch broke the news today (April 25) that Li Chen—who was a postdoc in the lab of Savio Woo, a noted gene therapy scientist—faked data that appeared in four published studies, four National Institutes of Health (NIH) grant applications, and a submitted manuscript that was never published.

Six papers from the Woo lab were retracted from PNAS, the Journal of the National Cancer Institute, Human Gene Therapy, and Molecular Therapy in 2010. Chen was listed as an author on four of those papers. The ORI found that Chen, “intentionally, knowingly, and recklessly fabricated and falsified data reported in four (4) publications, one (1) submitted manuscript, and four (4) grant applications” that claimed to report a cure for phenylketonuria, or PKU, in mice.

Apparently, Chen fudged 19 figures, including images that illustrated the chromosomal locations of integration sites, reported the use of PCR to determine integration frequencies, and represented the detection of chromosomal translocations in human cells, among other fabrications. In some cases, Chen indicated that gene therapy experiments were successful when in ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies